Genprex Story

<div class='circular--portrait' style='background:#347AFC;color: #ffffff;font-size:3em;'>GNP</div>
GNPX -- USA Stock  

USD 3.40  0.22  6.08%

As many millenniums are trying to avoid healthcare space, it makes sense to break down Genprex a little further and try to understand its current market patterns. As expected, Genprex is starting to reaffirm its true potential as investors are becoming more and more confident in the future outlook. The returns on the market and returns on Genprex appear slightly correlated for the last few months. Weak basic indicators of the company may also suggest signs of long term losses for Genprex investors. The stock experiences an active upward rally.
Published over a month ago
View all stories for Genprex | View All Stories
Planning to continue with Genprex (NASDAQ:GNPX) in September?
Genprex's average rating is Strong Buy from 1 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on Genprex market sentiment investors' perception of the future value of Genprex. Let us look at a few aspects of Genprex technical analysis.
Using predictive technical analysis, we will analyze different prices and returns patterns and diagnose historical swings to determine the real value of Genprex. In general, we focus on analyzing Genprex stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Genprex's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of Genprex's intrinsic value. In addition to deriving basic predictive indicators for Genprex, we also check how macroeconomic factors affect Genprex price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.

How does Genprex Stands against Peers?

Analyzing Genprex competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to Genprex across multiple sectors and thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be.
Check out Genprex Competition Details

How Genprex utilizes its cash?

To perform a cash flow analysis of Genprex, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Genprex is receiving and how much cash it distributes out in a given period. The Genprex cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Genprex Net Cash Flow from Operations is fairly stable at the moment as compared to the past year. Genprex reported Net Cash Flow from Operations of (6.92 Million) in 2019

Acquisition by Varner John Rodney of 530000 shares of Genprex subject to Rule 16b-3

Legal trades by Genprex insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Genprex insider trading alert for grant of stock option (right to buy) by Varner John Rodney, President & CEO, on 25th of August 2020. This event was filed by Genprex Inc with SEC on 2020-08-25. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Closer look at Genprex Semi Variance

Genprex has current Semi Variance of 17.74. Semi-variance provides a good measure of downside volatility for equity or a portfolio. It is similar to variance, but it only looks at periods where the returns are less than the target or average level.

Semi-variance is the square of semi-deviation. Semi-variance is calculated by averaging the deviations of returns that have a result that is less than the mean.

Semi Variance 
 = 
SUM(RET DEV)2 
N(ZERO) 
 = 
17.74
SUM = Summation notation
RET DEV = Actual return deviation over selected period
N(ZERO) = Number of points with returns less than zero
Let's now compare Genprex Semi Variance to its closest peers:
GNPX
EARS
DVAX
DYAI
DMAC
GNPX17.736990438093173
EARS22.84
DVAX34.99
DYAI14.71
DMAC27.28

Our take on today Genprex rise

Current Information Ratio is up to -0.01. Price may slide again. Genprex exhibits above-average semi-deviation for your current time horizon. We encourage investors to investigate Genprex individually to make sure intended market timing strategies and available technical indicagtors are consistent with their estimates about Genprex future systematic risk.

Our Final Perspective on Genprex

While some firms under the biotechnology industry are still a bit expensive, Genprex may offer a potential longer-term growth to investors. The inconsistency in the assessment between current Genprex valuation and our trade advice on Genprex is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Genprex.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Genprex. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com